Levosimendán Kalceks (Levosimendan)

Levosimendan binds to troponin C, increasing the heart muscle’s sensitivity to calcium and thereby enhancing contractile force without raising intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation that reduces afterload and supports cardiac output.

The dosing regimen for Levosimendán Kalceks is determined by the treating physician based on the patient’s clinical condition, severity of heart failure, and response to therapy. Prescribers set the infusion rate and duration according to current clinical guidelines and individual patient factors.

Safety data for levosimendan in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and clinicians should discuss uncertainties with the patient.

To request Levosimendán Kalceks, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and necessary import documentation.

The primary alternative to levosimendan is dobutamine, a catecholamine‑based inotrope. Unlike dobutamine, levosimendan increases contractility by calcium sensitization rather than raising intracellular calcium, which may reduce the risk of arrhythmias. Additionally, levosimendan provides vasodilation through potassium‑channel activation, offering combined inotropic and afterload‑reducing effects.

Levosimendán Kalceks must be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside this range.

Levosimendán Kalceks is given as an intravenous infusion. After reconstitution according to the product label, the solution is administered through a dedicated IV line, typically beginning with a loading dose followed by a continuous maintenance infusion, all under continuous hemodynamic monitoring.

The most serious adverse events include severe hypotension, myocardial ischemia, and potentially life‑threatening ventricular arrhythmias. Clinicians should monitor blood pressure, cardiac rhythm and signs of ischemia closely, especially during the initial loading phase and in patients with pre‑existing coronary disease.

Levosimendán Kalceks is contraindicated in patients with severe hypotension (systolic blood pressure < 90 mmHg), recent myocardial infarction, uncontrolled arrhythmias, or known hypersensitivity to levosimendan or any excipients. Caution is also advised in severe hepatic impairment and in patients receiving other potent vasodilators.